Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug…
Ziwig Endotest: Scientific Validation Published in NEJM Evidence
LYON, France, Dec. 2, 2025 /PRNewswire/ -- NEJM Evidence, a journal of…
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025
EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V.…
Worlds Leading Scientific Supercomputing Centers Adopt NVIDIA NVQLink to Integrate Grace Blackwell Platform With Quantum Processors
News Summary: NVIDIA NVQLink to be broadly adopted by more than a…
NVIDIA and RIKEN Advance Japans Scientific Frontiers With New Supercomputers for AI and Quantum Computing
News Summary: Two new RIKEN supercomputers for scientific AI and quantum computing,…
George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Associations Scientific Sessions 2025
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage…
Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025
November 09, 2025 09:00 ET | Source: Medera Inc. BOSTON, Nov. 09,…
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.…
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”)…
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential…
